Compare DIN & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIN | LAB |
|---|---|---|
| Founded | 1958 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.8M | 347.5M |
| IPO Year | 1994 | 2008 |
| Metric | DIN | LAB |
|---|---|---|
| Price | $36.50 | $0.91 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 1 |
| Target Price | ★ $29.00 | $1.35 |
| AVG Volume (30 Days) | 350.4K | ★ 6.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | ★ 0.57 | 0.33 |
| Revenue | ★ $879,300,000.00 | $101,937,000.00 |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | $0.64 | $2.63 |
| P/E Ratio | $64.04 | ★ $2.77 |
| Revenue Growth | ★ 8.25 | N/A |
| 52 Week Low | $19.58 | $0.70 |
| 52 Week High | $39.68 | $1.72 |
| Indicator | DIN | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 67.76 | 52.79 |
| Support Level | $24.69 | $0.90 |
| Resistance Level | $39.68 | $1.02 |
| Average True Range (ATR) | 1.48 | 0.07 |
| MACD | 0.22 | 0.01 |
| Stochastic Oscillator | 90.71 | 92.80 |
Dine Brands Global Inc owns and franchises thousands of restaurants under the International House of Pancakes (IHOP), Applebee's Neighborhood Grill + Bar (Applebee's), and the Fuzzy's Taco Shop (Fuzzy's) names. The company conducts its business through three reportable segments: Franchise, Company-owned restaurants, and Rental. The majority of its revenue is generated from the Franchise segment, which consists of IHOP, Applebee's, and Fuzzy's franchise operations and generates revenue mainly from royalties and advertising fees from several IHOP, Applebee's, and Fuzzy's franchised restaurants, in addition to revenues from the sale of proprietary IHOP and Fuzzy's products to its franchisees. Geographically, the majority of the company's revenues is generated from its domestic market.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.